WallStSmart
ONCT

Oncternal Therapeutics Inc

NASDAQ: ONCT · HEALTHCARE · BIOTECHNOLOGY

$0.53
+0.00% today

Updated 2026-06-03

Market cap
$1.56M
P/E ratio
P/S ratio
0.72x
EPS (TTM)
$-11.69
Dividend yield
52W range
$0 – $0
Volume

Oncternal Therapeutics Inc (ONCT) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-5,029.17%
Operating margin
-5,313.89%
ROE
-149.90%
ROA
-76.40%
Debt/equity
0.02x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2004$1.87M$-22.35M100.00%-1,247.67%-1,197.00%
2005$3.78M$-36.84M58.41%-1,019.54%-974.06%
2006$7.50M$-35.51M89.70%-513.22%-473.15%
2007$7.13M$-40.36M91.29%-638.56%-566.36%
2008$13.53M$-51.78M95.20%-402.76%-382.76%
2009$14.73M$-46.26M91.24%-316.72%-314.03%
2010$60.61M$15.29M98.73%22.98%25.23%
2011$14.74M$-33.29M92.84%-228.59%-225.89%
2012$-27.07M
2013$-42.11M
2014$-39.41M
2015$-18.70M
2016$-2.51M$-17.72M200.00%1,032.78%705.85%
2017$1.67M$-30.44M-459.32%-1,831.24%-1,818.34%
2018$2.52M$-38.42M98.18%-1,549.35%-1,523.92%
2019$2.42M$-15.91M-318.93%-1,365.28%-656.16%
2020$3.38M$-17.21M100.00%-519.76%-509.90%
2021$4.32M$-31.30M100.00%-726.91%-725.38%
2022$1.49M$-43.39M100.00%-3,016.58%-2,912.28%
2023$785000.00$-39.48M-3,690.19%-5,313.89%-5,029.17%

Frequently asked questions

What is Oncternal Therapeutics Inc's revenue?

Oncternal Therapeutics Inc's trailing twelve-month revenue is $2.16M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ONCT?

In its most recent fiscal year, ONCT ran a gross margin of -3,690.19%, an operating margin of -5,313.89%, and a net margin of -5,029.17%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ONCT generate?

ONCT produced $-32.16M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ONCT's balance sheet healthy?

ONCT holds $6.70M in cash and equivalents against — in long-term debt, on $30.05M of shareholder equity. That debt is best read against the cash flow the business throws off each year.